名称 | MM3122 |
描述 | MM3122 (MM-3122) is a selective type II transmembrane serine protease (TMPRSS2) inhibitor, IC50 = 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells. |
体外活性 | MM3122 (0-1 μM) exhibits inhibitory activity against HGFA, matriptase, hepsin, and thrombin with IC50 values of 32 nM, 0.31 nM, 0.19 nM, and over 20 nM, respectively. Additionally, MM3122 (0.1-100 μM) inhibits SARS-CoV-2 calu-3, MERS VSV pseudotype calu-3, and VSV-SARS CoV-2 chimera calu-3 with EC50 values of 74 nM, 0.87 nM, and 0.43 nM, respectively [1]. |
体内活性 | MM3122, administered intraperitoneally (i.p.) at doses ranging from 0-100 mg/kg daily for 7 days, showed no adverse effects, including no weight loss or changes in harvested organs (liver, spleen, and kidney), when compared to control subjects. Additionally, a single i.p. dose of MM3122 at 16.7 mg/kg was found to have a plasma half-life of 8.6 hours and a lung half-life of 7.5 hours in NSG mice[1]. |
存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 90 mg/mL (135.2 mM), Sonication is recommended.
|
关键字 | MM3122 | GTPL-11533 | GTPL 11533 | MM 3122 |
相关产品 | Nirmatrelvir | EIDD-1931 | Remdesivir | Andrographolide | Silymarin | Umifenovir hydrochloride | Hydroxychloroquine | Ritonavir | Chloroquine phosphate | Chloroquine | Favipiravir | Imatinib |
相关库 | 经典已知活性库 | 抗病毒库 | 抑制剂库 | 已知活性化合物库 |